Your browser doesn't support javascript.
loading
Development of a fluorescence screening assay for binding partners of the iron-sulfur mitochondrial protein mitoNEET.
Newton, Ebenezer; Starcovic, Sarah A; Menze, Michael; Konkle, Mary E; Long, Timothy E; Hazlehurst, Lori A; Huber, Jason D; Robart, Aaron R; Geldenhuys, Werner J.
Afiliación
  • Newton E; C. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown WV 26501, USA.
  • Starcovic SA; Department of Biochemistry and Molecular Medicine, School of Medicine, West Virginia University, Morgantown WV 26506, USA.
  • Menze M; Department of Biology, University of Louisville, Louisville, KY, USA.
  • Konkle ME; Department of Chemistry, Ball State University, Muncie, IN, USA.
  • Long TE; Department of Pharmaceutical Sciences, School of Pharmacy, Marshall University, Huntington, WV 25755, USA.
  • Hazlehurst LA; Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown WV 26506, USA.
  • Huber JD; Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown WV 26506, USA.
  • Robart AR; Department of Biochemistry and Molecular Medicine, School of Medicine, West Virginia University, Morgantown WV 26506, USA.
  • Geldenhuys WJ; Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown WV 26506, USA; Department of Neuroscience, School of Medicine, West Virginia University, Morgantown, WV 26506, USA. Electronic address: werner.geldenhuys@hsc.wvu.edu.
Bioorg Med Chem Lett ; 89: 129310, 2023 06 01.
Article en En | MEDLINE | ID: mdl-37137430
ABSTRACT
MitoNEET belongs to the CDGSH Iron-Sulfur Domain (CISD)-gene family of proteins and is a [2Fe-2S] cluster-containing protein found on the outer membrane of mitochondria. The specific functions of mitoNEET/CISD1 remain to be fully elucidated, but the protein is involved in regulating mitochondrial bioenergetics in several metabolic diseases. Unfortunately, drug discovery efforts targeting mitoNEET to improve metabolic disorders are hampered by the lack of ligand-binding assays for this mitochondrial protein. We have developed a protocol amenable for high-throughput screening (HTS) assay, by modifying an ATP fluorescence polarization method to facilitate drug discovery targeting mitoNEET. Based on our observation that adenosine triphosphate (ATP) interacts with mitoNEET, ATP-fluorescein was used during assay development. We established a novel binding assay suitable for both 96- or 384-well plate formats with tolerance for the presence of 2% v/v dimethyl sulfoxide (DMSO). We determined the IC50-values for a set of benzesulfonamide derivatives and found the novel assay reliably ranked the binding-affinities of compounds compared to radioactive binding assay with human recombinant mitoNEET. The developed assay platform is crucial in identifying novel chemical probes for metabolic diseases. It will accelerate drug discovery targeting mitoNEET and potentially other members of the CISD gene family.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Hierro-Azufre Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Bioorg Med Chem Lett Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Hierro-Azufre Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Bioorg Med Chem Lett Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
...